SEC Form 4 · accession 0001225208-18-004012
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Pierce
Officer — SVP,Pres Urology,Pelvic Health
Period of report
Feb 21, 2018
Accepted (ET)
Feb 23, 2018 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 21, 2018 | S | 16,286 | $27.00 | D | 24,201 | D | |
| Common StockF3 | Feb 22, 2018 | M | 2,607 | $0.00 | A | 26,808 | D | |
| Common Stock | Feb 22, 2018 | F | 1,159 | $26.48 | D | 25,649 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF3,F4 | — | Feb 22, 2018 | M | 2,607 | D | — | Feb 22, 2021 | Common Stock | 2,607 | 7,821 | D |
Explanation of responses
- F1This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at $27.00 and $27.005. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F4Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.